Cargando…
Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-called oncogenic driver mutations) and the development of targeted agents interfering with the tumor-promoting intracellular signa...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217508/ https://www.ncbi.nlm.nih.gov/pubmed/28210142 http://dx.doi.org/10.2147/LCTT.S49490 |